Ingrid Zhang, Chief Executive Officer of Legend Biotech Corp, filed a Form 4 on September 16, 2026, disclosing the acquisition of 1,131,860 restricted share units on September 15, 2026, at a price of $0.
Key Highlights
- Reporting person: Ingrid Zhang, Chief Executive Officer of Legend Biotech Corp
- Securities acquired: 1,131,860 restricted share units (RSUs), each representing a contingent right to receive one ordinary share upon settlement
- Transaction price: $0 per unit, coded as an acquisition (A) on September 15, 2026
- Vesting schedule: One-third of the RSUs vest on each of September 15, 2027, September 15, 2028, and September 15, 2029, subject to continued service
- Beneficial ownership following transaction: 1,131,860 ordinary shares, held directly
- ADS note: Each American Depositary Share of the issuer represents two ordinary shares
RSU Grant Details for Legend Biotech Corp CEO Ingrid Zhang
According to the filing, Legend Biotech Corp (NASDAQ:LEGN) Chief Executive Officer Ingrid Zhang acquired 1,131,860 restricted share units on September 15, 2026, at a price of $0. The transaction, coded "A" in Table I of the Form 4, reflects a grant of non-derivative securities and is reported as a direct holding. Following the transaction, the filing lists Zhang's beneficial ownership of ordinary shares at 1,131,860.
The filing explains that each RSU "represents a contingent right to receive one ordinary share of the Issuer upon settlement." The vesting schedule, as disclosed, provides that one-third of the RSUs vest and become exercisable on each of September 15, 2027, September 15, 2028, and September 15, 2029, respectively, "subject to the Reporting Person's continued service to the Issuer on each such vesting date." No RSUs are scheduled to vest before September 15, 2027.
The filing also notes that ordinary shares of the issuer may be represented by American Depositary Shares, with each ADS representing two ordinary shares. The Form 4 was signed by Robert Staloff as Attorney-in-Fact on September 16, 2026, and filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. No derivative securities transactions were reported in Table II of the filing.
What Was Disclosed
The filing discloses an RSU grant of 1,131,860 units to Legend Biotech's CEO on September 15, 2026, at no cost, with equal vesting tranches over three years beginning September 15, 2027, contingent on continued service.



Please wait processing your request...